Dr Norbert Nabet
Head of Public Health, Ziwig
For millions of women, endometriosis remains a debilitating and underdiagnosed condition, often taking seven to 10 years to identify due to the limitations of current diagnostic methods.
Ziwig is transforming the field with pioneering technology, combining next-generation sequencing (NGS), salivary RNA analysis and artificial intelligence (AI) to provide a fast, reliable and non-invasive diagnostic solution: Ziwig Endotest®️.
AI-powered endometriosis diagnosis
The test uses salivary microRNA (miRNA) sequencing to identify patterns linked to endometriosis. Advanced AI algorithms analyse large datasets, quickly identifying miRNA patterns for accurate early-stage detection. This technology improves diagnosis, reduces uncertainty and speeds up access to appropriate care. With 97.4% sensitivity and 93.5% specificity, the test offers a precise alternative to invasive tests and symptom-based assessments, leading to better patient outcomes.
This salivary RNA technology
shows promise beyond endometriosis.
From innovation to global access
In a major step toward making early diagnosis more accessible, French health authorities have approved fast-track reimbursement for 25,000 patients across 80 specialised medical centres under the Innovation Funding framework. This marks a significant shift in addressing the diagnostic gap, ensuring timely care for thousands of women.
Ziwig Endotest®️ is already available across Europe and the Middle East, reaching 20 countries. Further expansion is underway in regions like Asia and South America, highlighting Ziwig’s commitment to making innovative diagnostic solutions available to women worldwide.
Beyond endometriosis: pioneering the future of diagnostics
This salivary RNA technology shows promise beyond endometriosis. The company is exploring new applications in oncology, neurology and gynaecology, with ongoing studies targeting ovarian cancer, amyotrophic lateral sclerosis (ALS) and other complex diseases. This breakthrough technology is paving the way for precision medicine, where non-invasive molecular diagnostics are standard for early detection.
Recognised for its innovation in women’s health, Ziwig was awarded the Galien International Prize 2024. The company are reshaping the way women’s health is prioritised, studied and treated. With Ziwig Endotest®️, a new era of faster, more precise and accessible diagnostics begins — empowering women and influencing the future of healthcare.
